Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hatchtech Pty. Ltd.

Latest From Sanofi KK

Sanofi Reaches For Post-Plavix Growth In Japan

While Sanofi’s Japanese pharma business is feeling the impact of generic competition to its former blockbuster top product, it is aiming to move back into growth through a string of planned launches over the next few years.

Japan Business Strategies

Biocon Confident As First Biosimilars Seen Hitting Europe In Early 2018

India’s leading biologics company Biocon has said it expects its first biosimilar products to be launched in the European market by early 2018 and is bullish on both its plans in the sector and earnings prospects after reporting quarterly net profit soared by a better than expected 52%.

India Biosimilars

Tresiba Solid As Novo Nordisk Plots Japan Growth

Novo Nordisk has had its best year ever in sales terms in Japan, where its subsidiary is benefiting mainly from the strong performance of basal insulin preparation Tresiba.

BioPharmaceutical Asia Pacific

New Japan Approvals Include Tafinlar, Tagrisso

The latest batch of drug approvals in Japan includes several novel oncology products, some of which have only recently been launched elsewhere, in a sign that applicants and regulators are trying to speed up local access to important new therapies.

BioPharmaceutical Asia Pacific
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Dermatology
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Australia
  • Parent & Subsidiaries
  • Hatchtech Pty. Ltd.
  • Senior Management
  • Hugh Alsop, CEO
    Vern Bowles, PhD, CSO
  • Contact Info
  • Hatchtech Pty. Ltd.
    Phone: 439 080 353
    697 Burke Rd., Ste. 201
    Camberwell, 3124